Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy

Abstract

The present application provides methods of treating a colon cancer (such as advanced and / or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticies comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody(such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6).

Description

[0001] Cross references to related applications [0002] This application claims priority to US Provisional Application No. 62 / 607,798 filed on December 19, 2017, the entire disclosure of which is incorporated herein by reference. Technical field [0003] The present invention relates to methods and compositions for the treatment of colon cancer-by including a composition comprising nanoparticles of mTOR inhibitors (such as limus drugs, such as sirolimus or its derivatives) and albumin, combined Anti-VEGF antibody and FOLFOX regimen. Background technique [0004] Colon cancer (colorectal cancer, CRC) has become a major health problem worldwide due to its high prevalence and high mortality. It is the third most common malignancy in developed countries and the second most common cause of cancer-related deaths. Although the progress of CRC treatment has had a significant impact on its management, many patients with advanced disease will eventually die from their cancer. [0005] The m...

AI Technical Summary

Problems solved by technology

Although therapeutic advances in CRC have had a major impact on its management, many patients with advanced disease will eventually succumb to their cancer

Images